Thursday, December 08, 2016 6:00:50 PM
Big Pharma is transforming right in front of our eyes and in the not too distant future, you may not recognize it. In fact, the next blockbuster treatment may not be a drug at all, but rather an electroceutical.
For over a century, medicine has centered on chemistry and biology to treat disease. However, that is rapidly changing toward the use devices that are capable of speaking the body's electric language to treat human ailments and diseases. This new age of medicine is commonly referred to as "Bioelectronic Medicine," and it seeks to use electroceuticals rather than drugs to treat disease.
Big Pharma has recognizes the potential of electroceuticals and has begun to invest heavily in this new field of medicine.
For example, GlaxoSmithKline has teamed up with Google's parent company to form a $715 million joint venture called Galvani Bioelectronics to develop and commercialize electroceutical products.
Merck & Co. invested in a non-invasive vagus nerve stimulator (VNS) to treat migraine headaches. Novartis is developing a smart contact-lens that will allow diabetics to monitor themselves continuously by measuring the glucose level in their tears; and Johnson & Johnson (J&J) has invested in an implantable electroceutical for treating heart failure.
One company that investors interested in biotech should take note of is Endonovo Therapeutics, Inc. (ENDV). It recently announced that it had signed a term sheet to raise $5 million from a strategic healthcare investor, as part of a larger $15 million round of financing to uplist the company onto a national stock exchange and to develop a pipeline targeting vascular diseases and ischemia/reperfusion injuries using its non-invasive electroceutical. ENDV's non-invasive technology, which it calls "Immunotronics", uses time variant magnetic pulses to control the inflammatory response and promote the formation of new blood vessels.
Some of the conditions that ENDV is targeting include ischemic stroke, myocardial infarction, peripheral artery disease, as well as ischemia/reperfusion injury in the liver and kidneys.
The life threatening and debilitating conditions that Endonovo is seeking to treat are among the largest with clinical unmet needs. For example, between 2012 and 2030, total direct medical stroke-related costs are projected to triple, from $71.6 billion to $184.1 billion, with the majority of the projected increase in costs arising from patients 65 to 79 years of age. Furthermore, over 6.8 million Americans are estimated to have peripheral artery disease, according to the American Heart Association.
http://www.cbs58.com/story/34002008/big-pharma-is-bullish-on-electroceuticals-should-you
Recent ENDV News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/02/2024 10:23:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:30:14 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/29/2023 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:08:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:03:32 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/25/2023 11:04:33 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:16:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM